核心观点2024 年公司持续践行降本增效，聚焦主业的经营战略，利润端亏损大幅收窄，符合24 年4 月可转债公告中对利润端的指引预期；但收入端增速略低于预期，主要系公司部分产品因国内行业集采、国家政策指导导致出厂价有所调整。展望2025 年，公司冠脉、骨科和心律管理业务有望维持稳健增长；手术机器人、神经介入、心脏瓣膜和主动脉及外周介入业务继续保持快速增长；同时集团自有产品出海有望在24 年1 亿美金...
Source Link核心观点2024 年公司持续践行降本增效，聚焦主业的经营战略，利润端亏损大幅收窄，符合24 年4 月可转债公告中对利润端的指引预期；但收入端增速略低于预期，主要系公司部分产品因国内行业集采、国家政策指导导致出厂价有所调整。展望2025 年，公司冠脉、骨科和心律管理业务有望维持稳健增长；手术机器人、神经介入、心脏瓣膜和主动脉及外周介入业务继续保持快速增长；同时集团自有产品出海有望在24 年1 亿美金...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.